References
- TamsmaJThe pathogenesis of malignant ascitesCancer Treat Res200713410911817633049
- AyantundeAAParsonsSLPattern and prognostic factors in patients with malignant ascites: A retrospective studyAnn Oncol200718594594917298959
- El-ShamiKElsaidAEl-KermYOpen-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascitesJ Clin Oncol200725Suppl 189043
- SchmittMSchmittAReinhardtPOpsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytesInt J Oncol200425484184815375531
- RufPGiresOJagerMFellingerKAtzJLindhoferHCharacterisation of the new EpCAM-specific antibody HO-3: Implications for trifunctional antibody immunotherapy of cancerBr J Cancer200797331532117622246
- ZeidlerRReisbachGWollenbergBSimultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killingJ Immunol199916331246125210415020
- ZeidlerRMysliwietzJCsanadyMThe Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cellsBr J Cancer200083226126610901380
- RiesenbergRBuchnerAPohlaHLindhoferHLysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3)J Histochem Cytochem200149791191711410615
- LitvinovSVVeldersMPBakkerHAFleurenGJWarnaarSOEp-CAM: A human epithelial antigen is a homophilic cell-cell adhesion moleculeJ Cell Biol199412524374468163559
- BalzarMWinterMJde BoerCJLitvinovSVThe biology of the 17–1A antigen (Ep-CAM)J Mol Med1999771069971210606205
- OstaWAChenYMikhitarianKEpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapyCancer Res200464165818582415313925
- WentPVaseiMBubendorfLFrequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancersBr J Cancer200694112813516404366
- WentPTLugliAMeierSFrequent EpCam protein expression in human carcinomasHum Pathol200435112212814745734
- SchmidtMHasencleverDSchaefferMPrognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancerClin Cancer Res200814185849585518794096
- SchmidtMPetryIBBohmDEp-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancerBreast Cancer Res Treat2010330 [Epub ahead of print].
- LitvinovSVBalzarMWinterMJEpithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherinsJ Cell Biol19971395133713489382878
- MunzMKieuCMackBSchmittBZeidlerRGiresOThe carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferationOncogene200423345748575815195135
- MaetzelDDenzelSMackBNuclear signalling by tumour-associated antigen EpCAMNat Cell Biol200911216217119136966
- LindhoferHSchoberthAPelsterDHessJHeroldJJagerMElimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: Results from a pivotal phase II/III studyJ Clin Oncol200927Suppl 15301419364954
- HirschhaeuserFWalentaSMueller-KlieserWEfficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of actionCancer Immunol Immunother201059111675168420652245
- HeissMMStrohleinMAJagerMImmunotherapy of malignant ascites with trifunctional antibodiesInt J Cancer2005117343544315906359
- BurgesAWimbergerPKumperCEffective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I/II studyClin Cancer Res200713133899390517606723
- HeissMMMurawaPKoralewskiPThe trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialInt J Cancer201012792209222120473913